Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14933

UPID:
UB2L6_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme L6; Retinoic acid-induced gene B protein; UbcH8; Ubiquitin carrier protein L6; Ubiquitin-protein ligase L6

ALTERNATIVE UPACC:
O14933; A6NDM6; A8MY53; Q8N5D8; Q9UEZ0

BACKGROUND:
The Ubiquitin/ISG15-conjugating enzyme E2 L6, also referred to as Retinoic acid-induced gene B protein and Ubiquitin carrier protein L6, is integral to the ubiquitin-proteasome system. It is involved in the targeted degradation of proteins, including key regulatory proteins like p53/TP53, through ubiquitination, highlighting its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ubiquitin/ISG15-conjugating enzyme E2 L6 offers promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.